Managing Patients With Concurrent High Risk for Bleeding and Thromboembolic Events

Area of Science:

• Cardiology
• Internal Medicine
• Clinical Research

Background:

• Increasing prevalence of patients with both high bleeding risk (HBR) and high thromboembolic risk (HTR).
• Conditions like gastrointestinal bleeding (GIH), acute coronary syndrome (ACS), and pulmonary embolism (PE) represent significant clinical challenges.
• Limited guidelines exist for managing the concomitant occurrence of HBR and HTR.

Observation:

• Patients with HBR can concurrently have HTR, leading to complex clinical scenarios.
• Management of these dual-risk patients is challenging, often resulting in critically ill individuals.
• Existing guidelines primarily address individual risks (GIH, ACS, PE) rather than their combined presentation.

Findings:

• Expert recommendations advocate for an integrated assessment of patient and intervention factors to guide antithrombotic therapy.
• Antithrombotic regimen duration and intensity should be tailored: more aggressive/longer for predominant thrombotic risk, de-escalated/shorter for higher bleeding susceptibility.
• The study presents two clinical cases to illustrate the complexities and decision-making processes involved.

Implications:

• Highlights the need for personalized antithrombotic strategies in patients with dual high risks.
• Emphasizes the critical balance between preventing thrombosis and minimizing bleeding complications.
• Suggests a framework for clinical decision-making in managing these challenging patient profiles.